Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

Condition:   Stroke
Intervention:   Other: Time-To-Treatment Randomization
Sponsors:   University of Texas at Austin;   Lone Star Stroke Research Consortium;   Texas Department of State Health Services
Not yet recruiting - verified January 2017

Use of Electronic Personal Health Records to Improve Medication Adherence

Conditions:   Atrial Fibrillation;   Medication Adherence
Intervention:   Other: Medication Education
Sponsors:   Parkview Health;   Centers for Medicare and Medicaid Services
Completed - verified January 2017

Preoperative Carbohydrate Load and Intraoperative w3-PUFA in CAGB Surgery

Conditions:   Atrial Fibrillation Rapid;   Postoperative Complications
Interventions:   Dietary Supplement: CHO (carbohydrate);   Drug: intravenous w-3 PUFA;   Other: CHO (carbohydrate) plus intravenous w3-PUFA
Sponsor:   Federal University of Mato Grosso do Sul
Completed - verified January 2017

Effect of Low Dose ColchiciNe on the InciDence of POAF

Conditions:   Atrial Fibrillation;   Cardiac Surgery;   Colchicine Adverse Reaction
Interventions:   Drug: Colchicine;   Drug: Placebo Oral Tablet
Sponsor:   Jordan Collaborating Cardiology Group
Not yet recruiting - verified January 2017

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Other: Mobile Application Intervention;   Drug: Rivaroxaban
Sponsor:   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: Vernakalant;   Drug: Flecainide
Sponsors:   David Filgueiras-Rama;   Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Recruiting - verified January 2017

Opportunistic Screening in Pharmacies for Atrial Fibrillation in Seniors (>65 Years)

Condition:   Incidence of Atrial Fibrillation in Adults Aged ≥ 65
Intervention:  
Sponsors:   RWTH Aachen University;   Apothekerverband Aachen e.V.;   Pfizer
Recruiting - verified January 2017

SmartWATCHes for Detection of Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Five minutes pulse wave recording
Sponsors:   University Hospital, Basel, Switzerland;   University Hospital Greifswald
Recruiting - verified January 2017

Clinical Study for Workflow and Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System for Treating Symptomatic Paroxysmal AF (QDOT-Micro)

Condition:   Atrial Fibrillation
Intervention:   Device: THERMOCOOL SMARTTOUCH® SF-5D catheter
Sponsor:   Biosense Webster, Inc.
Recruiting - verified January 2017

Chloroquine for Symptomatic Persistent and Longstanding Persistent AF

Condition:   Atrial Fibrillation
Intervention:   Drug: Chloroquine Phosphate
Sponsor:   University of South Florida
Recruiting - verified January 2017

Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation

Condition:   Nonvalvular Atrial Fibrillation
Intervention:  
Sponsors:   Harvard Clinical Research Institute;   American College of Cardiology
Recruiting - verified September 2016

Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm

Conditions:   Atrial Fibrillation;   Venous Thromboembolism;   Pulmonary Embolism
Interventions:   Other: XAPPORT;   Other: Expert Panel ("gold standard")
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting - verified January 2017

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Review of the Safety and Effectiveness of the THERMOCOOL SMARTTOUCH® SF Catheter Evaluated for Treating Symptomatic PersistenT AF (PRECEPT)

Condition:   Atrial Fibrillation
Intervention:   Device: THERMOCOOL SMARTTOUCH® SF catheter
Sponsor:   Biosense Webster, Inc.
Recruiting - verified January 2017

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

Condition:   Stroke
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients

Condition:   Arrhythmia
Intervention:   Drug: Colchicine
Sponsor:   Jordan Collaborating Cardiology Group
Completed - verified January 2017

Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: pulmonary veins ablation's successful outcome
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2017

Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies

Condition:   Atrial Fibrillation
Intervention:   Drug: Vitamin K Antagonist
Sponsors:   Bayer;   Janssen Research & Development, LLC
Active, not recruiting - verified January 2017

COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

Condition:   Atrial Fibrillation
Intervention:   Drug: Colchicine group
Sponsor:   Elpen Pharmaceutical Co. Inc.
Active, not recruiting - verified January 2017

Multi-Channel Esophageal ECG Signal Classification

Conditions:   Atrial Fibrillation;   Atrial Function;   Arrhythmias, Cardiac;   Atrial Premature Complexes
Intervention:  
Sponsors:   University Hospital Inselspital, Berne;   Bern University of Applied Sciences
Completed - verified January 2017

mHealth Screening to Prevent Strokes

Condition:   Atrial Fibrillation
Interventions:   Device: iRhythm ZIO XT Patch;   Device: Wristband by Amiigo
Sponsors:   Scripps Translational Science Institute;   Janssen Scientific Affairs, LLC;   Aetna, Inc.
Enrolling by invitation - verified January 2017

Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Device: Single lead ECG device;   Device: 7-Day Holter monitor.
Sponsors:   Leiden University Medical Center;   Haaglanden Medisch Centrum;   Groene Hart Ziekenhuis;   Herning Hospital;   Alrijne Hospital
Recruiting - verified January 2017

SMART China, A Multi-center Clinical Registry Study

Condition:   Atrial Fibrillation
Intervention:   Device: THERMOCOOL® SMARTTOUCH™
Sponsor:   Biosense Webster, Inc.
Active, not recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

WATCHMAN Implantation During Hybrid Ablation

Conditions:   Atrial Fibrillation;   Stroke
Intervention:   Device: WATCHMAN Device implantation
Sponsors:   Maastricht University Medical Center;   Boston Scientific Corporation
Completed - verified January 2017

Hybrid Versus Catheter Ablation in Persistent AF

Condition:   Atrial Fibrillation
Interventions:   Procedure: Hybrid Ablation;   Procedure: Catheter Ablation
Sponsor:   Maastricht University Medical Center
Recruiting - verified January 2017

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb
Recruiting - verified January 2017

Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Artery Bypass;   Antiplatelet Agents
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsor:   Ruijin Hospital
Active, not recruiting - verified January 2017

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Completed - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Cardioversion;   Cerebrovascular Stroke
Interventions:   Procedure: Cardioversion;   Drug: Oral Anticoagulant
Sponsor:   Suleyman Demirel University
Active, not recruiting - verified January 2017

Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED

Conditions:   Atrial Fibrillation;   Atrial Flutter
Intervention:   Device: drug-shock vs shock only
Sponsors:   Ottawa Hospital Research Institute;   The Ottawa Hospital
Recruiting - verified January 2017

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

The Concomitant Cryomaze Procedure Using Nitreous Oxide Cryoprobe: Comparison With Argon Based Cryoprobe

Conditions:   Atrial Fibrillation;   Valve
Interventions:   Device: Cryomaze procedure using Nitrous oxide;   Device: Cryomaze procedure using Argon
Sponsor:   Samsung Medical Center
Completed - verified March 2016

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Atrial Fibrillation Progression Trial

Condition:   Atrial Fibrillation
Interventions:   Device: Catheter Ablation;   Drug: Drug Treatment
Sponsor:   Biosense Webster, Inc.
Recruiting - verified January 2017

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Condition:   Severe Aortic Stenosis
Interventions:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI);   Procedure: Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm);   Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Sponsor:   Medtronic Cardiovascular
Recruiting - verified January 2017

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Conditions:   Fibrillation, Atrial;   Atrial Fibrillation
Intervention:   Drug: SB424323
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points